Federal Register / Vol. 79, No. 217 / Monday, November 10, 2014 / Notices 66723 

necessary for the proper performance of 

the FDIC’s functions, including whether 

the information has practical utility; (b) 

the accuracy of the estimates of the 

burden of the information collection, 

including the validity of the 

methodology and assumptions used; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the information collection on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

All comments will become a matter of 

public record. 

Dated at Washington, DC, this 5th day of 

November 2014. 

Federal Deposit Insurance Corporation. 

Robert E. Feldman, 

Executive Secretary. 

[FR Doc. 2014–26641 Filed 11–7–14; 8:45 am] 

BILLING CODE 6714–01–P 

GENERAL SERVICES 

ADMINISTRATION 

[Notice–CX–2014–01; Docket No. 2014– 

0002; Sequence 32] 

SES Performance Review Board 

AGENCY: General Services 

Administration. 

ACTION: Notice. 

SUMMARY: Notice is hereby given of the 

appointment of new members to the 

General Services Administration Senior 

Executive Service Performance Review 

Board. The Performance Review Board 

assures consistency, stability, and 

objectivity in the performance appraisal 

process. 

DATES: Effective: November 10, 2014. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Antonia T. Harris, Chief Human Capital 

Officer, Office of Human Resources 

Management, General Services 

Administration, 1800 F Street NW., 

Washington, DC 20405, 202–501–0398. 

SUPPLEMENTARY INFORMATION: Section 

4314(c)(1) through (5) of title 5 U.S.C. 

requires each agency to establish, in 

accordance with regulations prescribed 

by the Office of Personnel Management, 

one or more SES performance review 

board(s). The board is responsible for 

making recommendations to the 

appointing and awarding authority on 

the performance appraisal ratings and 

performance awards for the Senior 

Executive Service employees. 

The following have been designated 

as members of the Performance Review 

Board of the General Services 

Administration: 

Denise Roth, Deputy Administrator—Chair. 

Antonia T. Harris, Chief Human Capital 

Officer. 

Christine J. Harada, Associate Administrator 

for Governmentwide Policy. 

Giancarlo Brizzi, Principal Deputy Associate 

Administrator for Governmentwide Policy. 

Thomas A. Sharpe, Jr., Commissioner, 

Federal Acquisition Service. 

Kevin Youel Page, Deputy Commissioner, 

Federal Acquisition Service. 

Linda C. Chero, Regional Commissioner, 

Federal Acquisition Service, Mid-Atlantic 

Region. 

Norman S. Dong, Commissioner, Public 

Buildings Service. 

Michael S. Gelber, Deputy Commissioner, 

Public Buildings Service. 

George E. Northcroft, Regional Administrator, 

Northwest Arctic Region. 

Dated: November 3, 2014. 

Dan Tangherlini, 

Administrator. 

[FR Doc. 2014–26624 Filed 11–7–14; 8:45 am] 

BILLING CODE 6820–34–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3298–N] 

Medicare Program; Request for 

Nominations for Members for the 

Medicare Evidence Development & 

Coverage Advisory Committee 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

request for nominations for membership 

on the Medicare Evidence Development 

& Coverage Advisory Committee 

(MEDCAC). Among other duties, the 

MEDCAC provides advice and guidance 

to the Secretary of the Department of 

Health and Human Services (the 

Secretary) and the Administrator of the 

Centers for Medicare & Medicaid 

Services (CMS) concerning the 

adequacy of scientific evidence 

available to CMS in making coverage 

determinations under the Medicare 

program. The MEDCAC reviews and 

evaluates medical literature and 

technology assessments, and hears 

public testimony on the evidence 

available to address the impact of 

medical items and services on health 

outcomes of Medicare beneficiaries. 

DATES: Nominations must be received 

by Monday, December 8, 2014. 

ADDRESSES: You may mail nominations 

for membership to the following 

address: Centers for Medicare & 

Medicaid Services, Center for Clinical 

Standards and Quality, Attention: Maria 

Ellis, 7500 Security Boulevard, Mail 

Stop: S3–02–01, Baltimore, MD 21244 

or send via email to 

MEDCACnomination@cms.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Maria Ellis, Executive Secretary for the 

MEDCAC, Centers for Medicare & 

Medicaid Services, Center for Clinical 

Standards and Quality, Coverage and 

Analysis Group, S3–02–01, 7500 

Security Boulevard, Baltimore, MD 

21244 or contact Ms. Ellis by phone 

(410–786–0309) or via email at 

Maria.Ellis@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Secretary signed the initial 

charter for the Medicare Coverage 

Advisory Committee (MCAC) on 

November 24, 1998. A notice in the 

Federal Register (63 FR 68780) 

announcing establishment of the MCAC 

was published on December 14, 1998. 

The MCAC name was updated to more 

accurately reflect the purpose of the 

committee and on January 26, 2007, the 

Secretary published a notice in the 

Federal Register (72 FR 3853), 

announcing that the Committee’s name 

changed to the Medicare Evidence 

Development & Coverage Advisory 

Committee (MEDCAC). The charter for 

the committee can be accessed at http:// 

www.cms.gov/Regulations-andGuidance/Guidance/FACA/

MEDCAC.html. 

The MEDCAC is governed by 

provisions of the Federal Advisory 

Committee Act, Public Law 92–463, as 

amended (5 U.S.C. App. 2), which sets 

forth standards for the formulation and 

use of advisory committees, and is 

authorized by section 222 of the Public 

Health Service Act as amended (42 

U.S.C. 217A). 

We are requesting nominations for 

candidates to serve on the MEDCAC. 

Nominees are selected based upon their 

individual qualifications and not solely 

as representatives of professional 

associations or societies. We wish to 

ensure adequate representation of the 

interests of both women and men, 

members of all ethnic groups, and 

physically challenged individuals. 

Therefore, we encourage nominations of 

qualified candidates who can represent 

these interests. 

The MEDCAC consists of a pool of 

100 appointed members including: 94 

at-large standing members (6 of whom 

are patient advocates), and 6 

representatives of industry interests. 

Members generally are recognized 

authorities in clinical medicine 

including subspecialties, administrative 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
66724 Federal Register / Vol. 79, No. 217 / Monday, November 10, 2014 / Notices 

medicine, public health, biological and 

physical sciences, epidemiology and 

biostatistics, clinical trial design, health 

care data management and analysis, 

patient advocacy, health care 

economics, medical ethics or other 

relevant professions. 

The MEDCAC works from an agenda 

provided by the Designated Federal 

Official. The MEDCAC reviews and 

evaluates medical literature and 

technology assessments, and hears 

public testimony on the evidence 

available to address the impact of 

medical items and services on health 

outcomes of Medicare beneficiaries. The 

MEDCAC may also advise the Centers 

for Medicare & Medicaid Services (CMS) 

as part of Medicare’s ‘‘coverage with 

evidence development’’ initiative. 

II. Provisions of the Notice 

As of June 2015, there will be 16 

membership terms expiring. Of the 16 

memberships expiring, 2 are industry 

representatives, 1 is a patient advocate, 

and the remaining 13 membership 

openings are for the at-large standing 

MEDCAC membership. 

We wish to ensure adequate 

representation of the interests of both 

women and men, members of all ethnic 

groups and physically challenged 

individuals. Therefore, we encourage 

nominations of qualified candidates 

from these groups. 

All nominations must be 

accompanied by curricula vitae. 

Nomination packages should be sent to 

Maria Ellis at the address listed in the 

ADDRESSES section of this notice. 

Nominees are selected based upon their 

individual qualifications. Nominees for 

membership must have expertise and 

experience in one or more of the 

following fields: 

• Clinical medicine including 

subspecialties 

• Administrative medicine 

• Public health 

• Biological and physical sciences 

• Epidemiology and biostatistics 

• Clinical trial design 

• Health care data management and 

analysis 

• Patient advocacy 

• Health care economics 

• Medical ethics 

• Other relevant professions 

We are looking particularly for 

experts in a number of fields. These 

include cancer screening, genetic 

testing, clinical epidemiology, 

psychopharmacology, screening and 

diagnostic testing analysis, and vascular 

surgery. We also need experts in 

biostatistics in clinical settings, 

dementia treatment, minority health, 

observational research design, stroke 

epidemiology, and women’s health. 

The nomination letter must include a 

statement that the nominee is willing to 

serve as a member of the MEDCAC and 

appears to have no conflict of interest 

that would preclude membership. We 

are requesting that all curricula vitae 

include the following: 

• Date of birth 

• Place of birth 

• Social security number 

• Title and current position 

• Professional affiliation 

• Home and business address 

• Telephone and fax numbers 

• Email address 

• List of areas of expertise 

In the nomination letter, we are 

requesting that nominees specify 

whether they are applying for a patient 

advocate position, for an at-large 

standing position, or as an industry 

representative. Potential candidates will 

be asked to provide detailed information 

concerning such matters as financial 

holdings, consultancies, and research 

grants or contracts in order to permit 

evaluation of possible sources of 

financial conflict of interest. Department 

policy prohibits multiple committee 

memberships. A federal advisory 

committee member may not serve on 

more than one committee within an 

agency at the same time. 

Members are invited to serve for 

overlapping 2-year terms. A member 

may continue to serve after the 

expiration of the member’s term until a 

successor is named. Any interested 

person may nominate one or more 

qualified persons. Self-nominations are 

also accepted. Individuals interested in 

the representative positions must 

include a letter of support from the 

organization or interest group they 

would represent. The current 

Secretary’s Charter for the MEDCAC is 

available on the CMS Web site at: 

http://www.cms.hhs.gov/FACA/

Downloads/medcaccharter.pdf, or you 

may obtain a copy of the charter by 

submitting a request to the contact listed 

in the FOR FURTHER INFORMATION

CONTACT section of this notice. 

Authority: 5 U.S.C. App. 2, section 10(a)(1) 

and (a)(2). 

(Catalog of Federal Domestic Assistance 

Program No. 93.773, Medicare—Hospital 

Insurance; and Program No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program.) 

Dated: November 4, 2014. 

Patrick Conway, 

Deputy Administrator for Innovation and 

Quality and CMS Chief Medical Officer, 

Centers for Medicare & Medicaid Services. 

[FR Doc. 2014–26699 Filed 11–7–14; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0362] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Current Good 

Manufacturing Practice Regulations for 

Finished Pharmaceuticals 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the Agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal Agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension of an existing collection of 

information, and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

the current good manufacturing practice 

(CGMP) regulations for finished 

pharmaceuticals. 

DATES: Submit either electronic or 

written comments on the collection of 

information by January 9, 2015. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to: http://

www.regulations.gov. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA 305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: FDA 

PRA Staff, Office of Operations, Food 

and Drug Administration, 8455 

Colesville Rd., COLE–14526, Silver 

Spring, MD 20993–0002, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 


asabaliauskas on DSK5VPTVN1PROD with NOTICES